These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16596029)

  • 1. The pleiotropic effects of angiotensin receptor blockers.
    Chrysant SG; Chrysant GS
    J Clin Hypertens (Greenwich); 2006 Apr; 8(4):261-8. PubMed ID: 16596029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of suppressing the renin-angiotensin system on atrial fibrillation.
    Kalus JS; Coleman CI; White CM
    J Clin Pharmacol; 2006 Jan; 46(1):21-8. PubMed ID: 16397280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valsartan and recurrent atrial fibrillation.
    Tomoda H
    N Engl J Med; 2009 Jul; 361(5):532-3; author reply 533. PubMed ID: 19645082
    [No Abstract]   [Full Text] [Related]  

  • 6. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
    Chrysant SG; Chrysant GS
    J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.
    Chrysant SG
    J Hum Hypertens; 2005 Dec; 19(12):923-31. PubMed ID: 16049519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
    Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan in the treatment of heart attack survivors.
    Jugdutt BI
    Vasc Health Risk Manag; 2006; 2(2):125-38. PubMed ID: 17319456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P; Plouin PF
    Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
    Kuwabara Y; Komuro I
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):255-61. PubMed ID: 15768589
    [No Abstract]   [Full Text] [Related]  

  • 17. [Angiotensin receptor blockers--significance for the therapy of hypertension].
    Magometschnigg D
    Wien Med Wochenschr; 2001; 151(7-8):153-6. PubMed ID: 11450162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
    Coleman CI; Makanji S; Kluger J; White CM
    Ann Pharmacother; 2007 Mar; 41(3):433-7. PubMed ID: 17341525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.
    Bhatia V; Bhatia R; Mathew B
    Cardiol Rev; 2005; 13(6):297-303. PubMed ID: 16230887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.